Frantz S W, Beatty P W, English J C, Hundley S G, Wilson A G
Union Carbide Corporation, Bushy Run Research Center, Export, Pennsylvania 15632-8902.
Regul Toxicol Pharmacol. 1994 Jun;19(3):317-37. doi: 10.1006/rtph.1994.1027.
It has been recognized for several decades in the pharmaceutical industry that the safety evaluation of pharmacological agents must include pharmacokinetic (PK) studies, which are designed to determine the rate of absorption, distribution, metabolism, and excretion (ADME). In recent years the importance of such ADME studies in toxicology has also become increasingly apparent to the chemical industry. This increased focus has led to testing strategies that can produce ADME/PK data with greater applicability to toxicity testing and risk assessment. An example of such a strategy is the concept of a tiered approach to the conduct of ADME/PK studies (Wilson, A. G. E., Frantz, S. W., and Keifer, L. C. (1994). Environ. Health Perspect., in press). However, in practice, PK data are often viewed as being of limited usefulness and of only ancillary importance to the determination of chemical toxicity. As a consequence, the close integration of PK studies with toxicity-testing protocols is not always practiced within the chemical industry and is thus frequently scheduled independently from toxicity testing. This lack of integration has resulted in the design of subchronic (13-week) and chronic (2-year) toxicity studies without the benefit of PK information to establish the appropriate dose levels to be used, often because of inappropriate timing. The result is that much of the PK data which have been generated is without a clear consideration of its application to toxicity testing and risk assessment. This position paper is intended to provide recommendations for the appropriate design and interpretation of a PK study, as well as when and how to use PK data in the interpretation of toxicology data. Additional issues discussed in the paper include the design of PK studies to evaluate tissue time-course relationships and chemical persistence, the overall usefulness of PK data to toxicology testing, and the utility of PK as a useful interpretive and predictive tool in toxicology and risk assessment.
制药行业在几十年前就已经认识到,药物的安全性评估必须包括药代动力学(PK)研究,其目的是确定吸收、分布、代谢和排泄(ADME)的速率。近年来,化学工业也越来越明显地认识到这类ADME研究在毒理学中的重要性。这种关注度的提高催生了一些测试策略,这些策略能够生成更适用于毒性测试和风险评估的ADME/PK数据。这种策略的一个例子就是进行ADME/PK研究的分层方法概念(Wilson, A. G. E., Frantz, S. W., and Keifer, L. C. (1994). Environ. Health Perspect.,即将发表)。然而,在实际操作中,PK数据常常被认为用处有限,对于确定化学物质毒性而言仅具有辅助重要性。因此,化学工业内部并不总是将PK研究与毒性测试方案紧密结合,故而PK研究常常独立于毒性测试进行安排。这种缺乏整合的情况导致在设计亚慢性(13周)和慢性(2年)毒性研究时,没有利用PK信息来确定合适的剂量水平,这往往是由于时间安排不当所致。结果就是,所生成的许多PK数据在生成时并未明确考虑其在毒性测试和风险评估中的应用。本立场文件旨在就PK研究的恰当设计和解读,以及何时以及如何在解读毒理学数据时使用PK数据提供建议。本文还讨论了其他问题,包括评估组织时间进程关系和化学物质持久性的PK研究设计、PK数据对毒理学测试的总体有用性,以及PK作为毒理学和风险评估中有用的解释和预测工具的效用。